These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

588 related articles for article (PubMed ID: 8561197)

  • 41. Effect of haloperidol dose on iodine-123-IBZM brain SPECT imaging in schizophrenic patients.
    Vallabhajosula S; Hirschowitz J; Machac J
    J Nucl Med; 1997 Feb; 38(2):203-7. PubMed ID: 9025736
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response.
    Catafau AM; Corripio I; Pérez V; Martin JC; Schotte A; Carrió I; Alvarez E
    Psychiatry Res; 2006 Dec; 148(2-3):175-83. PubMed ID: 17059881
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.
    Kegeles LS; Slifstein M; Frankle WG; Xu X; Hackett E; Bae SA; Gonzales R; Kim JH; Alvarez B; Gil R; Laruelle M; Abi-Dargham A
    Neuropsychopharmacology; 2008 Dec; 33(13):3111-25. PubMed ID: 18418366
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Estimation of dopamine D2 receptor binding potential in the striatum with iodine-123-IBZM SPECT: technical and interobserver variability.
    Verhoeff NP; Kapucu O; Sokole-Busemann E; van Royen EA; Janssen AG
    J Nucl Med; 1993 Dec; 34(12):2076-84. PubMed ID: 8254390
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.
    Bigliani V; Mulligan RS; Acton PD; Ohlsen RI; Pike VW; Ell PJ; Gacinovic S; Kerwin RW; Pilowsky LS
    Psychopharmacology (Berl); 2000 Jun; 150(2):132-40. PubMed ID: 10907666
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders.
    Brücke T; Podreka I; Angelberger P; Wenger S; Topitz A; Küfferle B; Müller C; Deecke L
    J Cereb Blood Flow Metab; 1991 Mar; 11(2):220-8. PubMed ID: 1671782
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dopamine D2 receptor binding before and after treatment of major depression measured by [123I]IBZM SPECT.
    Klimke A; Larisch R; Janz A; Vosberg H; Müller-Gärtner HW; Gaebel W
    Psychiatry Res; 1999 Apr; 90(2):91-101. PubMed ID: 10482381
    [TBL] [Abstract][Full Text] [Related]  

  • 48. SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease.
    Tatsch K; Schwarz J; Oertel WH; Kirsch CM
    Nucl Med Commun; 1991 Aug; 12(8):699-707. PubMed ID: 1838142
    [TBL] [Abstract][Full Text] [Related]  

  • 49. D2 dopamine receptor up-regulation, treatment response, neurological soft signs, and extrapyramidal side effects in schizophrenia: a follow-up study with 123I-iodobenzamide single photon emission computed tomography in the drug-naive state and after neuroleptic treatment.
    Schröder J; Silvestri S; Bubeck B; Karr M; Demisch S; Scherrer S; Geider FJ; Sauer H
    Biol Psychiatry; 1998 May; 43(9):660-5. PubMed ID: 9582999
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide.
    Abi-Dargham A; Kegeles LS; Zea-Ponce Y; Mawlawi O; Martinez D; Mitropoulou V; O'Flynn K; Koenigsberg HW; Van Heertum R; Cooper T; Laruelle M; Siever LJ
    Biol Psychiatry; 2004 May; 55(10):1001-6. PubMed ID: 15121484
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dopamine D2 receptor imaging and neuroleptic drug response.
    Heinz A; Knable MB; Weinberger DR
    J Clin Psychiatry; 1996; 57 Suppl 11():84-8; discussion 89-93. PubMed ID: 8941175
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia.
    Lavalaye J; Linszen DH; Booij J; Reneman L; Gersons BP; van Royen EA
    Psychiatry Res; 1999 Nov; 92(1):33-44. PubMed ID: 10688158
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dopamine D2 receptor SPECT imaging: basic in vivo characteristics and clinical applications of 123I-IBZM in humans.
    Toyama H; Ichise M; Ballinger JR; Fornazzari L; Kirsh JC
    Ann Nucl Med; 1993 Feb; 7(1):29-38. PubMed ID: 8461237
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats.
    Scherfler C; Scholz SW; Donnemiller E; Decristoforo C; Oberladstätter M; Stefanova N; Diederen E; Virgolini I; Poewe W; Wenning GK
    Neuroimage; 2005 Feb; 24(3):822-31. PubMed ID: 15652317
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Cognition, schizophrenia and the effect of antipsychotics].
    Stip E
    Encephale; 2006; 32(3 Pt 1):341-50. PubMed ID: 16840928
    [TBL] [Abstract][Full Text] [Related]  

  • 56. D2 receptor occupancy during high- and low-dose therapy with the atypical antipsychotic amisulpride: a 123I-iodobenzamide SPECT study.
    la Fougère C; Meisenzahl E; Schmitt G; Stauss J; Frodl T; Tatsch K; Hahn K; Möller HJ; Dresel S
    J Nucl Med; 2005 Jun; 46(6):1028-33. PubMed ID: 15937316
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: a dual-isotope SPECT study.
    Yang YK; Yu L; Yeh TL; Chiu NT; Chen PS; Lee IH;
    Am J Psychiatry; 2004 Aug; 161(8):1496-8. PubMed ID: 15285982
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comfort, self-confidence, safety, and dopamine D2 receptor occupancy by antipsychotics.
    de Haan L; Lavalaye J; Booij J; Linszen D
    Am J Psychiatry; 2005 Aug; 162(8):1544-5. PubMed ID: 16055785
    [No Abstract]   [Full Text] [Related]  

  • 59. Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol.
    Corripio I; Catafau AM; Perez V; Puigdemont D; Mena E; Aguilar Y; Carrió I; Alvarez E
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):91-6. PubMed ID: 15610950
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of 123I-IBZM SPECT and 11C-raclopride PET findings in patients with parkinsonism.
    Schwarz J; Antonini A; Tatsch K; Kirsch CM; Oertel WH; Leenders KL
    Nucl Med Commun; 1994 Oct; 15(10):806-13. PubMed ID: 7838444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.